Recruiting TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% NCT07279402 Conditions Atezolizumab, Bronchial Neoplasms, Carcinoma, Bronchogenic, +11 more Locations Adana City Hospital — Adana, Turkey (Türkiye) Afyonkarahisar Health Sciences University Hospital — Afyonkarahisar, Turkey (Türkiye) Ankara Oncology Training and Research Hospital — Ankara, Turkey (Türkiye) Memorial Ankara Hospital — Ankara, Turkey (Türkiye) View all 25 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma NCT06609863 Conditions Adenocarcinoma, Advanced Hepatocellular Carcinoma, Atezolizumab, +12 more Locations Chinese PLA General hospital — Beijing, None Selected, China View Trial Details
Active, Not Recruiting The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications. NCT07233759 Conditions Atezolizumab, Digestive System Diseases, Digestive System Neoplasms, +7 more Locations National Taiwan University Hospital — Taipei, Taiwan View Trial Details
